Literature DB >> 4029512

Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein.

M Brownlee, H Vlassara, A Cerami.   

Abstract

Advanced nonenzymatic glycosylation products capable of cross-linking proteins accumulate on collagen in vivo in proportion to time-averaged blood glucose concentration. In this report, we have evaluated the ability of advanced nonenzymatic glycosylation products formed on collagen in vitro to covalently bind low-density lipoprotein (LDL) in a manner similar to that which occurs in human atherosclerotic lesions. At constant LDL concentration, covalent trapping increased linearly with the extent of advanced glycosylation product formation, from 1.42 +/- 0.15 to 4.46 +/- 0.36 micrograms LDL protein/mg collagen. At a constant level of collagen advanced glycosylation product, LDL binding increased as a function of increasing LDL concentration. At an LDL-cholesterol level of 103 mg/dl, covalent trapping of LDL by nonenzymatic glycosylation products on collagen averaged 3.2 times as much as control (P less than 0.01). These data indicate that LDL is bound specifically by reactive products generated by nonenzymatic glycosylation of collagen, and suggest that excessive LDL trapping by hyperglycemia-induced advanced glycosylation endproducts may contribute to the accelerated development of atherosclerosis in patients with diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4029512     DOI: 10.2337/diab.34.9.938

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  35 in total

1.  An in vitro study on the role of metal catalyzed oxidation in glycation and crosslinking of collagen.

Authors:  G B Sajithlal; P Chithra; G Chandrakasan
Journal:  Mol Cell Biochem       Date:  1999-04       Impact factor: 3.396

2.  [The role of AGEs and ROS in atherosclerosis].

Authors:  Alin Stirban
Journal:  Herz       Date:  2010-05       Impact factor: 1.443

3.  Glycated type 1 collagen induces endothelial dysfunction in culture.

Authors:  Pei-Ching Kuo; Cheng-Heng Kao; Jan-Kan Chen
Journal:  In Vitro Cell Dev Biol Anim       Date:  2007-10-03       Impact factor: 2.416

Review 4.  Advanced glycation end products, diabetes and ageing.

Authors:  N Nass; B Bartling; A Navarrete Santos; R J Scheubel; J Börgermann; R E Silber; A Simm
Journal:  Z Gerontol Geriatr       Date:  2007-10       Impact factor: 1.281

Review 5.  Lipoprotein alterations in diabetes mellitus.

Authors:  G M Kostner; I Karádi
Journal:  Diabetologia       Date:  1988-10       Impact factor: 10.122

Review 6.  Advanced glycation end products and diabetic retinopathy.

Authors:  Yashodhara Sharma; Sandeep Saxena; Arvind Mishra; Anita Saxena; Shankar Madhav Natu
Journal:  J Ocul Biol Dis Infor       Date:  2013-04-19

7.  Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats.

Authors:  H P Hammes; S S Ali; M Uhlmann; A Weiss; K Federlin; K Geisen; M Brownlee
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

Review 8.  RAGE: a novel target for drug intervention in diabetic vascular disease.

Authors:  Barry I Hudson; Ann Marie Schmidt
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

9.  Advanced glycation end products contribute to amyloidosis in Alzheimer disease.

Authors:  M P Vitek; K Bhattacharya; J M Glendening; E Stopa; H Vlassara; R Bucala; K Manogue; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

Review 10.  Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease.

Authors:  Susan J Zieman; David A Kass
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.